Vince Martin

Vince Martin

Vince Martin has written investing advice for several years, covering stocks across a range of industries. A former registered representative, Martin saw the dot-com bubble inflate and burst in real time, creating a healthy respect for downside risk. He splits his time between Chicago and rural Wisconsin with his wife and three dogs.

Recent Articles

The 10 Best Stocks for a “Set It and Forget It” Summer Portfolio

You can go away in May, but don't sell! Instead, go long in these 10 best stocks for summertime peace of mind, then hit the beach.

General Electric Company (GE) Stock Is a Problem Investment

General Electric Company (GE) stock is at a six-month low. But a host of problems facing GE stock mean the stock could call further.

Why Snap Inc (SNAP) Stock Isn’t As Ugly As It Looks

Snap Inc (SNAP) did post solid growth numbers in its first quarters. But investor expectations for SNAP stock were simply too high.

The 3 Key Risks Qualcomm, Inc. (QCOM) Stock Is Facing

Qualcomm stock is cheap at less than 13x 2017 estimates. But a number of risks facing QCOM stock justify that multiple.

3 Stocks to Buy Thanks to Big Post-Earnings Discounts

Investors overreacted to earnings from VRTV, S and AMD -- and created three stocks to buy for smart people looking for bargains.

Why Groupon Inc (GRPN) Stock Is Far Too Scary to Be a Good Bargain

Groupon (GRPN) earnings knocked the stock down 13%. But that doesn't mean Groupon stock presents a buying opportunity.

3 Reasons Advanced Micro Devices, Inc. (AMD) Stock Will Rebound

AMD stock was punished after Q1 earnings. But the long-term story for Advanced Micro Devices still holds. New chips and better margins are on the way.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Can Bounce Now

Teva Pharmaceutical's first-quarter earnings and reaffirmed guidance are good enough, and should at least drive a relief rally in TEVA stock.

Nvidia Corporation (NVDA) Stock Finally Erupts With Stellar Q1

NVDA stock finally was rocked out of its slumber by a monster Q1 and stellar Q2 guidance that negates much of the bear case against Nvidia.

Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Still Hot Garbage

Valeant Pharmaceuticals flipped to a profit in Q1, and VRX stock is jumping by double digits. But Valeant's long-term issues haven't budged.